Case Number 4681
Request Date 22/03/2016
Completion Date 18/04/2016 

 

Details of the Request

1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?

 

2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?

  • Dasatinib (Sprycel)
  • Imatinib (Glivec)
  • Nilotinib (Tasigna)
  • Ponatinib (Iclusig)
  • Bosutinib (Bosulif)

 

3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?

 

4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?

 

5. Of these patients how many are currently being treated with each of the following TKIs?

  • Dasatinib (Sprycel)
  • Imatinib (Glivec)
  • Nilotinib (Tasigna)
  • Ponatinib (Iclusig)
  • Bosutinib (Bosulif)
  • Other (i.e. not on a TKI)

 

Details of the Response

1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?

34

 

2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?

  • Dasatinib (Sprycel) - 6
  • Imatinib (Glivec) - 19
  • Nilotinib (Tasigna) - 9
  • Ponatinib (Iclusig) - 0
  • Bosutinib (Bosulif) - 0

 

3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?

1 patient

 

4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?

0 patients were treated

 

5. Of these patients how many are currently being treated with each of the following TKIs?

  • Dasatinib (Sprycel) - None
  • Imatinib (Glivec) - None
  • Nilotinib (Tasigna) - None
  • Ponatinib (Iclusig) - None
  • Bosutinib (Bosulif) - None
  • Other (i.e. not on a TKI) - None